mc2-CMX
The mc2-CMX vaccine is a live attenuated vaccine that was developed using M. tuberculosis Ag85, MPT-51 and HSP-x to generate a fusion protein called CMX. The nucleotide sequences corresponding to epitopes 85 to 159 bp of Ag85C and 91 to 112 bp of MPT51 and HSP-x. The gene sequence was inserted in the genome of…
Read MoreALHA
Ag85A-LpqH (AL) is a recombinant subunit vaccine that combines the T cell-stimulating antigen Ag85A with the humoral immunity-targeting antigen LpqH. It is constructed using the pET-21a(+) vector, expressed in E. coli BL21(DE3), and formulated with aluminum for subcutaneous administration.
Read MoreAd5-105K
The Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) developed by CanSino Biologics Inc. is a non-replicating viral-vectored vaccine intended for administration via nebulized inhalation by mouth. It is designed to induce both local mucosal immunity in the respiratory tract and systemic immune responses against Mycobacterium tuberculosis (Mtb). The adenovirus type 5 (Ad5) backbone functions as…
Read MoreTBvac-1, TBvac-2, TBvac-10
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Read MoreLm::Mtb9Ag
This TB vaccine candidate comprises a live attenuated Listeria monocytogenes vector with two major virulence gene deletions and a T-cell immunity enhancing mutation (Lm ΔactA ΔinlB prfA*) that expresses nine M. tuberculosis immunoprotective proteins (Mpt64, TB10.4, ESAT-6, CFP10, Ag85B, EsxN, PPE68, EspA, and TB8.4 – four absent from BCG) from two chromosomal fusion protein expression…
Read More